Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2012-11-08 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is a media release announcing that the FDA advisory committee has recommended approval of the drug Signifor for Cushing's disease. It includes clinical trial results, drug information, and forward-looking statements. There are no financial statements or detailed financial performance data. The document is a regulatory announcement about a drug approval process and clinical trial results, not a financial report or earnings release. It is not a full annual or interim report, nor a call transcript or management report. Given the nature of the document as a regulatory filing reporting material news about the company, it fits best under Regulatory Filings (RNS). The document length is about 13,460 characters, which is substantial but the content is a press release/reporting event rather than a financial report. Therefore, the classification is RNS with high confidence.
2012-11-08 English
NOVARTIS PHASE III STUDY SHOWS RLX030 IMPROVED SYMPTOMS AND REDUCED DEATHS BY ON
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis International AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is a media release announcing the results of a Phase III clinical study (RELAX-AHF) showing the efficacy of RLX030 in treating acute heart failure. The document primarily provides clinical trial results, study details, and forward-looking statements about the drug development and regulatory discussions. It does not contain comprehensive financial statements, management discussion and analysis, or detailed regulatory filings. It is a regulatory announcement of clinical trial results and related information rather than a financial report or earnings release. Form 6-K filings typically serve as regulatory filings to disclose material information by foreign private issuers. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2012-11-07 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis International AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is a media release about regulatory updates lifting precautionary holds on Novartis seasonal influenza vaccines. It is not a full financial report, audit report, or earnings release. It is a regulatory announcement providing information to the SEC and the public about a material event related to the company. The document length is 9176 characters, which is substantial but the content is clearly a press release-type regulatory update rather than a financial report or management discussion. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2012-11-01 English
NOVARTIS TO START CONSTRUCTION OF NEW BIOTECHNOLOGY FACILITY IN SINGAPORE.
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is a media release announcing the start of construction of a new biotechnology facility in Singapore, including details about the investment, strategic rationale, and expected timelines. There are no financial statements, quarterly or annual financial results, or detailed financial analysis included. The document is primarily an announcement of a corporate development and investment plan, not a financial report or earnings release. It is also not a regulatory certification or officer attestation. Given the nature of the content and the form type (6-K), this filing fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories. The document length (over 11,000 characters) indicates it is not a brief announcement of a report publication (RPA). Therefore, the classification is RNS with high confidence.
2012-10-31 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is a media release about the safety and efficacy of seasonal influenza vaccines produced in Italy, including a precautionary halt by the Italian ministry of health. The document does not contain financial statements or detailed financial analysis. It is a regulatory announcement providing information to the market and regulators about a specific operational issue. The length is 6526 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. There is no indication that this is an annual or interim financial report, audit report, or earnings release. It is not a call transcript, management change, or capital update. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into other specific categories.
2012-10-26 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer submitted to the SEC under the Securities Exchange Act of 1934. It references exhibits including a Financial Report for Q3 2012 and an Interim Financial Report, but the document itself is a submission notice rather than the full report. The document length is short (1497 characters), and it primarily serves as a cover or notification filing. According to the rules, such filings are classified as Regulatory Filings (RNS) because they do not contain the full financial data but rather announce or submit reports.
2012-10-25 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.